Since loss-of-function mutations in SCN9A were first identified as the cause of CIP in 20064, there has been wide interest in the development of selective NaV1.7 inhibitors for treatment of pain35. This evidence concerns the gene SCN9A and hereditary sensory and autonomic neuropathy.